Download PDF
Gastroenterologie up2date 2017; 13(02): 110-111
DOI: 10.1055/s-0043-106078
Wichtige Studien im Fokus
Georg Thieme Verlag KG Stuttgart · New York

Kommentar

Christoph Lübbert
Further Information

Publication History

Publication Date:
03 July 2017 (online)

Also available at
    Permissions and Reprints All articles of this category

Comment on:

Antikörpertherapie verhindert Rezidive einer Clostridien-KolitisGastroenterologie up2date 2017; 13(02): 109-110
DOI: 10.1055/s-0043-105787

Wilcox MH et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med 2017; 376: 305 – 317
 

    • Literatur

    • 1 Lessa FC, Mu Y, Bamberg WM. et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-834
      CrossrefPubMedGoogle Scholar
    • 2 Lübbert C, Zimmermann L, Borchert J. et al. Epidemiology and recurrence rates of clostridium difficile infections in Germany: a secondary data analysis. Infect Dis Ther 2016; 5: 545-554
      CrossrefPubMedGoogle Scholar
    • 3 Cammarota G, Ianiro G, Tilg H. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569-580
      CrossrefPubMedGoogle Scholar
    • 4 Wilcox MH, Gerding DN, Poxton IR. et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376: 305-317
      CrossrefPubMedGoogle Scholar
    • 5 Heimann SM, Vehreschild JJ, Cornely OA. et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection 2015; 43: 707-714
      CrossrefPubMedGoogle Scholar